Anti human tigit pe

Manufactured by BioLegend

Anti-human TIGIT-PE is a laboratory reagent used to detect and study the TIGIT (T-cell immunoreceptor with Ig and ITIM domains) protein, which is expressed on the surface of T cells and other immune cells. It is conjugated to the fluorescent dye phycoerythrin (PE) for use in flow cytometry and related applications.

Automatically generated - may contain errors

Lab products found in correlation

Viability dye, by Cytek Biosciences (2 mentions) Cd19 car detection reagent, by Miltenyi Biotec (2 mentions) Anti human cd8 bv785, by BioLegend (2 mentions) Anti human cd62l bv421, by BioLegend (2 mentions) Anti human cd25 viobright fitc, by Miltenyi Biotec (2 mentions) Anti human cd3 apc h7, by BD (2 mentions) Facsaria fusion, by BD (2 mentions) Anti human cd27 pe cf594, by BD (2 mentions)

2 protocols using anti human tigit pe

CD8+ CAR T Cell Sorting and TCR Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cryopreserved GMP product cells were thawed at 37°C and washed. Cells were, then, stained with the CD19-CAR Detection reagent (Miltenyi; Cat# 130-115-965) for 10 minutes at room temperature followed by staining with an anti-biotin antibody conjugated to APC (Miltenyi; Cat# 130-110-952) and a cocktail of antibodies (CD3, CD8, CD27, CD62L, CD25, and TIGIT) and a viability dye (Tonbo Biosciences; Cat# 13-0870-T100). After staining for 10 minutes at room temperature, the cells were washed twice and resuspended in FACS buffer for sorting on the FACSAria Fusion (BD Biosciences). CD8+ CAR T cells with either the predicted effector surface profile (TIGIT+, CD62L^lo and CD27-) or the opposite, non-effector precursor profile (TIGIT-, CD62L+, and CD27+) were sorted into complete RPMI media. Cells were lysed with Trizol for bulk TCR repertoire sequencing.
Antibodies used were anti-human CD3-APC-H7 (BD Pharmingen; Cat #560176), anti-human CD8-BV785 (Biolegend; Cat # 344740), anti-human CD27-PE-CF594 (BD Horizon; Cat # 562297), anti-human CD62L-BV421 (Biolegend; Cat # 304828), anti-human CD25-VioBright FITC (Miltenyi Biotec; Cat# 130-113-283), and anti-human TIGIT-PE (Biolegend; Cat# 372703).

Wilson T.L., Kim H., Chou C.H., Langfitt D., Mettelman R.C., Minervina A.A., Allen E.K., Métais J.Y., Pogorelyy M.V., Riberdy J.M., Velasquez M.P., Kottapalli P., Trivedi S., Olsen S.R., Lockey T., Willis C., Meagher M.M., Triplett B.M., Talleur A.C., Gottschalk S., Crawford J.C, & Thomas P.G. (2022). Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages. Cancer Discovery, 12(9), 2098-2119.

+ Open protocol

+ Expand

Sorting of Effector and Precursor CAR T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cryopreserved GMP product cells were thawed at 37°C and washed. Cells were then stained with the CD19-CAR detection reagent (Miltenyi; cat. #130-115-965) for 10 minutes at room temperature followed by staining with an antibiotin antibody conjugated to APC (Miltenyi; cat. #130-110-952), a cocktail of antibodies (CD3, CD8, CD27, CD62L, CD25, and TIGIT), and a viability dye (Tonbo Biosciences; cat. #13-0870-T100). After staining for 10 minutes at room temperature, the cells were washed twice and resuspended in FACS buffer for sorting on the FACSAria Fusion (BD Biosciences). CD8⁺ CAR T cells with either the predicted effector surface profile (TIGIT⁺, CD62L^lo, and CD27⁻) or the opposite, noneffector precursor profile (TIGIT⁻, CD62L⁺, and CD27⁺) were sorted into complete RPMI media. Cells were lysed with TRIzol for bulk TCR repertoire sequencing.
Antibodies used were anti-human CD3-APC-H7 (BD Pharmingen; cat. #560176), anti-human CD8-BV785 (BioLegend; cat. #344740), anti-human CD27-PE-CF594 (BD Horizon; cat. #562297), anti-human CD62L-BV421 (BioLegend; cat. #304828), anti-human CD25-VioBright FITC (Miltenyi Biotec; cat. #130-113-283), and anti-human TIGIT-PE (BioLegend; cat. #372703).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!